LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- The Trip Report by Beckley Waves, a leading publication on the business, science,…
HOUSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that…
Mental health and sobriety platform launches to provide sobriety resources to those facing challenges with their drinking PHILADELPHIA, Aug. 2,…
Calgary, Alberta--(Newsfile Corp. - August 1, 2023) - The Newly Institute Inc. ("Newly" or the "Company") wishes to announce that,…
Vancouver, British Columbia--(Newsfile Corp. - August 1, 2023) - Safe Supply Streaming Co. Ltd. ("Safe Supply" or "SSSC" or "the…
Tel Aviv, Israel / Vancouver, Canada, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE:…
-A Phase 2a study of BAER-101 in epilepsy is planned to initiate in 2024MIAMI, Aug. 01, 2023 (GLOBE NEWSWIRE) --…
Sale Completes Awakn's Exit From Healthcare Services To Focus Solely on Biotechnology Research and DevelopmentToronto, Ontario--(Newsfile Corp. - August 1,…
This announcement contains inside informationStrategic Divestment of C4XD's Orexin-1 Receptor Antagonist Programme to Indivior for £15.95 MillionSale encompasses all rights…
OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading…